Omeros Corporation Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Omeros (OMER) Tops Q3 EPS by 8c, Revenues Beat
November 12, 2019 4:15 PM ESTOmeros (NASDAQ: OMER) reported Q3 EPS of ($0.33), $0.08 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $29.86 million versus the consensus estimate of $27.24 million.
Third Quarter 2019 Financial Highlights
3Q 2019 revenues were $29.9 million, another quarter of record sales of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. This compares to $26.8 million in 2Q 2019, an increase of $3.1 million, or 12 percent.Net loss in 3Q 2019 was $16.5 million, or $0.33 per share. This compares to a net loss $14.5 million, or... More